Triglyceride Levels, Alirocumab Treatment, and Cardiovascular Outcomes After an Acute Coronary Syndrome.
急性冠狀動脈症候群後的三酸甘油脂水平、Alirocumab 治療與心血管結果。
J Am Coll Cardiol 2024-09-04
SGLT2-inhibition increases total, LDL, and HDL cholesterol and lowers triglycerides: Meta-analyses of 60 randomized trials, overall and by dose, ethnicity, and drug type.
SGLT2抑制劑增加總膽固醇、LDL膽固醇和HDL膽固醇,降低三酸甘油脂:60個隨機試驗的荟萃分析,整體和按劑量、族裔和藥物類型分析。
Atherosclerosis 2023-08-15
Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of 3 Tests.
將此醫學文章的標題翻譯為繁體中文:將脂蛋白(a)濃度與急性冠狀動脈症候群後心血管事件風險相關聯:三種測試的比較。
Circulation 2024-04-03
Cardiovascular outcomes in patients with coronary artery disease and elevated lipoprotein(a): implications for the OCEAN(a)-outcomes trial population.
冠狀動脈疾病患者中心血管結果及高脂蛋白(a)水平:對OCEAN(a)-outcomes試驗人群的意義。
Eur Heart J Open 2023-08-29
Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: a report from the ODYSSEY OUTCOMES study.
Alirocumab在急性冠狀動脈症候群後根據性別和脂蛋白(a)的心血管結果:ODYSSEY OUTCOMES研究報告。
J Clin Lipidol 2024-07-03
Role and impact of a specialized cardiometabolic clinic in managing high-risk patients with type 2 diabetes and atherosclerotic cardiovascular disease.
專門心血管代謝診所對於管理高風險2型糖尿病及動脈粥樣硬化心血管疾病患者的角色與影響。
Am J Prev Cardiol 2024-07-29